Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Immunoglobulin Light-chain Amyloidosis 2Paraproteinemias 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Amyloidosis 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene × 1 year × Clear all
NCT07624760 2026-06-03

MGUS-PET

University of Zurich

Phase NA Not yet recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

NCT04392960 2026-04-16

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase NA Completed
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡